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Introduction
Genome-wide scans and resequencing efforts have recently 
revealed hundreds of recurrent copy-number alterations (CNAs) 
and point mutations across diverse human cancers. However, 
genomic instability and heterogeneity of human tumors impedes 
a straightforward cataloguing of cancer-causing genes and of 
possible therapeutic targets. Strategies enabling the distinction of 
causal genetic alterations (drivers) from bystander genomic noise 
(passengers) are needed to facilitate the discovery of genes that 
drive oncogenesis. Although several approaches have recently 
been described, the statistical power of these approaches depends 
on very large sample numbers (1). Another major limitation of 
human cancer-genome characterization studies is the lack of rig-
orous in vivo functional validation. Studies that include function-
al data invariably rely upon transfection studies in cultured cells, 
which lack many hallmarks of naturally arising tumors (2). There is 
therefore the pressing need to combine comparative oncogenomic 
approaches with in vivo cancer models to identify and validate new 
bona fide cancer genes/pathways that drive cancer progression 
and/or metastasis.
Malignant melanoma is one of the most aggressive and treat-
ment-resistant human cancers. Improvement of clinical outcomes 
for this disease remains a major challenge. Despite the recent 
developments in melanoma therapies, most of the patients with 
metastatic melanoma still succumb to their disease (3). The molec-
ular genetics of melanoma, and in particular how specific genom-
ic and nongenomic (epigenetic) alterations interact to produce its 
aggressive/metastatic characteristics, remain poorly understood. 
This lack of knowledge has been a major barrier to rational devel-
opment of effective therapeutics and prognostic diagnostics for 
melanoma patients. One confounding factor of discriminating 
drivers in human melanoma is the particularly high background 
mutation burden due to UV mutagenesis (4).
Substantial progress in our understanding of the etiologies 
and genetic underpinnings of melanoma has nevertheless been 
made and has led to promising results in trials of targeted ther-
apies for this disease. A key advance was the discovery of the 
recurrent somatic mutations in the gene encoding the BRAF ser-
ine-threonine kinase, the BRAFV600E mutation being the most 
common, in about 50% of patients (5). Large single-center studies, 
meta-analyses, and whole-exome sequencing (WES)  efforts have 
Identification and functional validation of oncogenic drivers are essential steps toward advancing cancer precision 
medicine. Here, we have presented a comprehensive analysis of the somatic genomic landscape of the widely used 
BRAFV600E- and NRASQ61K-driven mouse models of melanoma. By integrating the data with publically available genomic, 
epigenomic, and transcriptomic information from human clinical samples, we confirmed the importance of several 
genes and pathways previously implicated in human melanoma, including the tumor-suppressor genes phosphatase and 
tensin homolog (PTEN), cyclin dependent kinase inhibitor 2A (CDKN2A), LKB1, and others. Importantly, this approach 
also identified additional putative melanoma drivers with prognostic and therapeutic relevance. Surprisingly, one of 
these genes encodes the tyrosine kinase FES. Whereas FES is highly expressed in normal human melanocytes, FES 
expression is strongly decreased in over 30% of human melanomas. This downregulation correlates with poor overall 
survival. Correspondingly, engineered deletion of Fes accelerated tumor progression in a BRAFV600E-driven mouse model 
of melanoma. Together, these data implicate FES as a driver of melanoma progression and demonstrate the potential of 
cross-species oncogenomic approaches combined with mouse modeling to uncover impactful mutations and oncogenic 
driver alleles with clinical importance in the treatment of human cancer.
Comparative oncogenomics identifies tyrosine kinase 
FES as a tumor suppressor in melanoma
Michael Olvedy,1,2 Julie C. Tisserand,3 Flavie Luciani,1,2 Bram Boeckx,4,5 Jasper Wouters,6,7 Sophie Lopez,3 Florian Rambow,1,2  
Sara Aibar,6,7 Bernard Thienpont,4,5 Jasmine Barra,1,2 Corinna Köhler,1,2 Enrico Radaelli,8 Sophie Tartare-Deckert,9 Stein Aerts,6,7 
Patrice Dubreuil,3 Joost J. van den Oord,10 Diether Lambrechts,4,5 Paulo De Sepulveda,3 and Jean-Christophe Marine1,2
1Laboratory for Molecular Cancer Biology, Center for Cancer Biology, Vlaams Instituut voor Biotechnologie (VIB), Leuven, Belgium. 2Laboratory for Molecular Cancer Biology, Department of Oncology, 
KU Leuven, Leuven, Belgium. 3INSERM, Aix Marseille University, CNRS, Institut Paoli-Calmettes, CRCM, Equipe Labellisée Ligue Contre le Cancer, Marseille, France. 4Laboratory for Translational Genetics, 
Center for Cancer Biology, VIB, Leuven, Belgium. 5Laboratory for Translational Genetics, 6Laboratory of Computational Biology, Department of Human Genetics, KU Leuven, Leuven, Belgium. 7Laboratory of 
Computational Biology, 8Mouse Histopathology Core Facility, VIB Center for Brain & Disease Research, Leuven, Belgium. 9Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM, U1065, Université 
Côte d’Azur, Nice, France. 10Laboratory of Translational Cell and Tissue Research, Department of Pathology, KU Leuven and UZ Leuven, Leuven, Belgium.
Authorship note: M. Olvedy, J.C. Tisserand, and F. Luciani are co–first authors. D. Lam-
brechts, P. De Sepulveda, and J.C. Marine are co–senior authors.
Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: October 21, 2016; Accepted: March 2, 2017.
Reference information: J Clin Invest. https://doi.org/10.1172/JCI91291.
Downloaded from http://www.jci.org on May 5, 2017.   https://doi.org/10.1172/JCI91291
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 jci.org
Strikingly, somatic variants were rare in all lesions, with an 
average of 1.33 missense mutations per lesion (Supplemental Fig-
ure 1A). In total, 16 mutations were identified and independently 
validated using an orthogonal genotyping method. Notably, loss 
of Trp53 did not significantly increase the number of missense 
mutations (Supplemental Figure 1A and Supplemental Table 2). 
Likewise, we identified and independently validated only 1 single 
indel across all 12 lesions. This indel caused a frameshift deletion 
in Fbxw22 and is predicted to cause a loss-of-function phenotype 
(Supplemental Figure 1A). The number of missense mutations in 
each lesion was significantly lower than in sun-exposed human 
melanoma (8). Similarly to non–sun-exposed human melanoma 
(8), we failed to identify a specific mutational signature or muta-
tional bias (Supplemental Figure 1B), due to low mutation burden.
Consistent with the low mutation burden, we identified only 
1 recurrent missense mutation in A230050P20Rik. However, this 
mutation was found in 2 different tumors isolated from the same 
mouse, indicating that these lesions are likely to be clonally related 
as opposed to being driven by an independent recurrent event. None 
of the missense mutations were found in genes that are known to be 
significantly (q ≤ 0.05) mutated in human melanoma according to 
MutSig2CV analysis (Broad Institute TCGA Genome Data Analysis 
Center – 2016: Mutation Analysis; MutSig2CV v3.1). Nevertheless, 
in the cohort of human melanomas from TCGA (n = 290), 4 out of 
14 orthologous genes were recurrently mutated and 8 harbored pro-
tein-inactivating mutations such as nonsense or splice-site muta-
tions or frameshift deletions (Supplemental Table 2).
Recurrent CNAs in murine melanomas. To assess the role of 
chromosomal aberrations in BRAFV600E- and NRASQ61K-driven 
melanomas, whole-genome shallow sequencing (WGSS) was per-
formed and the landscape of somatic CNAs was established based 
on read depth. In total we sequenced 70 primary melanoma lesions 
(Figure 1 and Supplemental Table 1) derived from 35 BRAFV600E- 
and 35 NRASQ61K-mutant mice. Among the BRAFV600E-driven mel-
anoma lesions, 7 were engineered to lack Ink4a, 6 had conditional 
deletion of Pten (14), 6 were knockouts for Cdkn2a locus, and 10 
carried a Trp53R172H mutation frequently observed in UV-exposed 
human melanoma (19, 24). Of the NRASQ61K-driven lesions, 5 had 
deletion in Ink4a, 5 had deletion of the full Cdkn2a locus, and 16 
carried conditional deletion in at least 1 of the Trp53 alleles.
Chromosomal aberrations — both in terms of whole-chro-
mosomal (broad) and focal CNAs — were significantly higher in 
NRASQ61K- than in BRAFV600E-driven tumors (Supplemental Figure 
2A). Nevertheless, GISTIC (https://software.broadinstitute.org/
software/cprg/?q=node/31) identified recurrently deleted regions 
in BRAFV600E-driven melanoma, encompassing well-established 
tumor-suppressor genes, including Cdkn2a and Cdkn2b (11%; q = 
1.76 × 10–1) and Pten (26%; q = 4.20 × 10–2) as well as Trp53 and Nf1 
(14%, q = 3.40 × 10–2; Figure 2, A–D, and Supplemental Table 3 for 
an overview of all recurrently deleted loci). Whereas chromosome 
12 (harboring, among other tumor suppressors, p27Kip1) and chro-
mosome 19 (harboring Pten) were significantly deleted (17%, q = 
2.80 × 10–5 and 17%, q = 2.80 × 10–5, respectively), amplification 
of chromosome 6, which contains Kras and c-Raf, was frequently 
observed (23%, q = 2.73 × 10–9; Figure 2A).
In addition to few other recurrent focal CNAs (Supplemen-
tal Table 3), GISTIC identified 3 distinct regions located next to 
subsequently confirmed that BRAFV600E mutations are among the 
most common activating genetic events detected in cutaneous 
melanomas (4, 6–8). Accordingly, mice engineered to express 
BRAFV600E in melanocytes develop melanoma at a median laten-
cy of 12.6 months (9). This mutation overactivates the MAPK/
ERK signaling pathway, leading to melanocytic hyperproliferation 
(10). Importantly, BRAFV600E-mutant melanomas are addicted to 
this oncogenic driver mutation and targeted therapies against the 
BRAFV600E-activated oncogene have demonstrated very effective 
antitumor responses in patients (11, 12). Activation of the MAPK 
signaling pathway in about 20% of cutaneous melanoma is a con-
sequence of NRAS mutations (6), and melanocyte-specific expres-
sion of NRASQ61K drives melanoma formation in mice (13).
Both BRAFV600E- and NRASQ61K-driven mouse melanoma 
lesions recapitulate many histopathological features that are 
seen in subsets of human melanomas (9, 13–15). The long latency 
in these models (>10 months) indicates that additional genomic 
alterations are required for tumor progression. Loss-of-function 
mutations in phosphatase and tensin homolog (PTEN), cyclin 
dependent kinase inhibitor 2A (CDKN2A), or cyclin-dependent 
kinase inhibitor 2A (INK4A) and transformation related protein 53 
(TRP53), events that are frequently observed in human melanoma 
(16), have been shown to increase the penetrance and reduce the 
latency of these BRAFV600E- and/or NRASQ61K-driven mouse mela-
noma lesions (13, 14, 17–20). Importantly, since these melanoma 
lesions develop in the absence of UV exposure, the background 
mutation frequency is likely to be dramatically reduced. We there-
fore hypothesized that these models are well suited for a compara-
tive cancer genome study aimed at identifying genetic events that 
drive melanoma initiation and progression in cooperation with 
oncogenic BRAF and NRAS and, importantly, validating their rel-
evance in the appropriate in vivo context.
Results
Low mutation burden in murine melanoma. In an effort to identify 
novel melanoma drivers, BRAFV600E- and NRASQ61K-driven spon-
taneous cutaneous melanoma mouse lesions were subjected to 
WES at an average coverage depth of ×60 (Supplemental Table 1; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI91291DS1). BRAFV600E-driven lesions lacking 
p16INK4A (thereafter referred to as INK4A) in the melanocyte lin-
eage (Tyr-CreERT2/° BrafLSL–V600E/+ Ink4a–/– mice) and NRASQ61K–mel-
anoma lacking both Trp53 alleles (Trp53-null) in the melanocyte 
lineage (Tyr-Cre Tyr-NrasQ61K/° Trp53fl/fl mice) were also analyzed 
(21, 22). Note that although the loss of these tumor suppres-
sors accelerated melanomagenesis, frank cutaneous melanoma 
lesions only appeared on average after 57 weeks in the absence of 
Ink4a and after 30 weeks on the Trp53-null background. In total, 
8 BRAFV600E-driven (2 of which originated from the same mouse) 
and 4 NRASQ61K-driven melanoma lesions were sequenced (Sup-
plemental Figure 1A). We also sequenced matching germline DNA 
from each intercross (4 Tyr-CreERT2/° BrafLSL–V600E/+ Ink4a–/–, 2 Tyr-
NrasQ61K/° and 2 Tyr-Cre Tyr-NrasQ61K/° Trp53fl/fl) at an average cov-
erage depth of ×60. We identified all somatic variants in these 12 
melanoma lesions using an established pipeline that had been pre-
viously used to reliably identify a large number of carcinogen-in-
duced somatic mutations in mouse squamous cell carcinomas (23).
Downloaded from http://www.jci.org on May 5, 2017.   https://doi.org/10.1172/JCI91291
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3jci.org
Whole-chromosome aberrations, and in particular losses (of 
chromosomes 1, 3, 7, 10, 11, 12, 18, and 19), were especially fre-
quent in samples carrying conditional deletion in one or both Trp53 
alleles (Figure 1 and Figure 2C, Supplemental Figure 2C, Supple-
mental Figure 3A, and Supplemental Table 5). Importantly, quan-
titative reverse-transcriptase PCR (RT-qPCR) analysis revealed 
that Trp53 mRNA levels in all Trp53 heterozygous lesions were 
comparable to those seen in Trp53-null lesions, indicating that all 
4 heterozygous lesions underwent Trp53 loss of heterozygosity 
(LOH) (Supplemental Figure 4A). These data indicate that there 
is a selective pressure for p53 loss of function on this background 
and that p53 deficiency promotes aneuploidy in skin melanoma. 
A similar phenomenon was recently described for nonmelanoma 
skin cancer (23) and was also observed in mouse liver cancers in 
which the p53 pathway was functionally inactivated (Supplemen-
tal Figure 4B). Interestingly, comparing the results from GISTIC 
of different tumor types — including data from murine SCLCs (27) 
and cutaneous SCCs (23) — indicated that the recurrent broad 
alterations are cancer-type specific (Supplemental Figure 4C). For 
instance, whereas loss of chromosome 19 (harboring Pten) was 
commonly seen in all tumor types, except liver carcinoma, ampli-
fication of chromosome 4 or loss of chromosome 9 was a very fre-
quent event only in mouse small cell lung cancers (mSCLCs) and 
one another on chromosome 6, which are recurrently amplified 
in NRASQ61K-driven lesions (Figure 2, B and D, and Supplemental 
Table 3 and 4). One of these regions encompasses 31 genes, includ-
ing Braf (68%, q = 1.05 × 10–16). The adjacent region contains 72 
genes, including Smo (68%, q = 5.50 × 10–19), which encodes a key 
transducer of hedgehog (Hh) signaling (25), and the third region 
did not carry any known or predicted oncogenes. The Braf-contain-
ing region was no longer significantly amplified when all lesions, 
including the BRAFV600E-driven melanoma, were included in GIS-
TIC, indicating that this particular focal event specifically occurs 
on an NRASQ61K-mutant background. Notably, none of these 3 
regions were amplified in NRASQ61K lesions that carried inactivat-
ing mutations within the Trp53 locus, indicating the loss of p53 
alleviates the need for these focal amplification events. In contrast, 
2 focal losses on chromosome 8 (13%, q = 1.03 × 10–1), encompass-
ing a single gene (Csmd1), and chromosome 14 (25%, q = 1.21 × 
10–2), encompassing 24 genes, were only observed in Trp53-null 
NRASQ61K lesions (Figure 2C). Interestingly, Csmd1 is a tumor sup-
pressor frequently deleted and mutated in human melanoma and 
is commonly lost in many other tumor types (26). Overall, these 
data indicate that broad and focal CNAs are likely to influence the 
progression of BRAFV600E- and NRASQ61K-driven tumors by affect-
ing regions harboring established and novel putative cancer genes.
Figure 1. Landscape of CNAs in genetically induced murine melanomas. Heat map of CNAs in 70 BRAFV600E- and NRASQ61K-driven murine melanomas. The 
genetic background of each sample is color coded based on the legend provided at the bottom of the panel. The copy-number gains and losses are depict-
ed in red and blue, respectively. Chromosome numbers are shown on the x axis. The total number of CNAs (focal and broad) is shown on the right panel.
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Figure 2. GISTIC analysis of recurrent 
genetic alterations in murine melano-
mas. Recurrent focal and whole-chro-
mosomal amplification and deletion in 
BRAFV600E-driven lesions (A; n = 35); 
NRASQ61K-driven, Trp53 WT lesions (B;  
n = 19); NRASQ61K-driven, Trp53 heterozy-
gous or homozygous null lesions (C;  
n = 16); and all samples combined (D;  
n = 70). Recurrent deletions and amplifica-
tions are shown in red and blue, respec-
tively. The green dashed lines in all panels 
indicate the set significance threshold of 
0.25. Genes of interest are listed next to 
focal gains and losses, and the numbers 
of protein-coding genes in the peak of the 
CNA are shown in parentheses.
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Single-nucleotide alterations (SNAs) were identified in 17 genes, 
and the promoter region of 396 genes exhibited evidence of DNA 
hypermethylation, an epigenetic mark that typically associates 
with repression of transcription (28, 29). Importantly, 30 of these 
genes had already been enlisted into various tumor-suppressor 
gene (TSG) databases, including UniProt (http://www.uniprot.
org/) and that referenced by Vogelstein et al. (Table 1 and Sup-
plemental Table 6; ref. 30). Webgestalt (http://webgestalt.org/
option.php), KEGG (http://www.genome.jp/kegg/genes.html), 
GeneSetDB (http://genesetdb.auckland.ac.nz/haeremai.html), 
and Ingenuity Pathway Analysis (IPA) (QIAGEN) revealed a sig-
nificant enrichment in genes implicated in pathways known to 
play important roles in melanomagenesis such as TGF-β (Padj = 
4.7 × 10–5), Wnt/β-catenin (Padj. = 1.1 × 10–5), the MAPK signaling 
pathway (Padj. = 5.5 × 10–5), Hh (Padj = 2.4 × 10–2) and p53 signaling 
(Padj = 1.3 × 10–3), and biological processes regulating the cell cycle 
(Padj. = 2.0 × 10–9), apoptosis (Padj. = 2.0 × 10–9), and cell movement 
(Padj. = 3.0 × 10–10). IPA also indicated that the majority of these 
genes (23 out of 30, 76%) have multiple biological functional 
connections, indicating that this list is enriched for alterations/
mutations affecting functionally interacting proteins (Supple-
mental Figure 6 and Supplemental Table 7).
Strikingly, virtually all of the genes validated as tumor sup-
pressors in the BRAFV600E- and/or NRASQ61K-driven melanoma 
mouse models, namely Pten, Cdkn2b, Nf1, Trp53, and Stk11, were 
among the 30 selected genes (Table 1; ref. 14, 31–34). Sporadic 
mutations and/or downregulation of expression of APC (35) and 
PDCD4 (36) in human melanoma have also been described. Inter-
estingly, one of these genes was the well-established negative reg-
ulator of the Hh signaling pathway, Sufu. Notably, Kctd11, another 
negative modulator of this pathway, was present among the 30 
putative melanoma TSGs that have not been previously linked to 
melanomagenesis (Table 1). These data, together with the identi-
fication of Smo in a focally and recurrently amplified region of the 
mouse melanoma genome (Figure 2B), indicate that increased Hh 
signaling may contribute to melanomagenesis.
Importantly, further in silico analysis of the RNA-sequencing 
(RNA-seq) data set from the melanoma TCGA cohort revealed 
significant clinical associations between the RNA abundance of 9 
(out of 30) genes and patient survival (P < 0.1; Table 1 and Sup-
plemental Table 6, ref. 37). Only one of these genes (i.e., PTEN) 
has been previously linked to melanoma. Together, these analyses 
identified a series of new likely drivers and progression pathways 
with clinical importance in human melanoma.
A tumor-suppressor function for FES in human melanoma. Giv-
en that the central aim of this study was the identification of new 
melanoma drivers with clinical relevance to the human disease, 
we focused our attention on the 8 above-described genes that 
have not been previously implicated in melanoma biology, name-
ly NKX3-1, PRDM1, AGAP2, TNFAIP3, FES, KCTD11, RAP1A, and 
BCL10. Importantly, analysis of a microarray data set (38) identi-
fied KCTD11, FES, and TNFAIP3 as the only 3 genes that — sim-
ilarly to PTEN — exhibited average lower levels of expression in 
a series of melanoma cell lines compared with various normal 
human melanocyte cultures (Supplemental Figure 7A). Interest-
ingly, only one of these genes (FES) showed a robust inverse cor-
relation between RNA abundance and DNA methylation levels 
nonmelanoma skin carcinomas, respectively. Similarly, recurrent 
loss of chromosome 10 was only observed in mouse melanoma.
Comparative genomics identifies putative melanoma drivers. 
GISTIC indicated that some of the focal and broad alterations 
described above occurred more frequently than expected by 
chance, suggesting that these events provide selective advan-
tage during tumor progression and may therefore involve key 
cancer (and/or melanoma) genes. Importantly, these events are 
of potential clinical relevance in human melanoma, as a signifi-
cant overlap between orthologous genes located on broad CNAs 
in human and murine melanoma was observed (Supplemental 
Figure 5, A–D). To begin cross-species analysis of human can-
cer and murine melanoma genomes, we compiled a list of genes 
located in chromosomal regions (both focal and broad CNAs) 
that are recurrently and specifically deleted in mouse melanoma 
lesions (n = 5204 genes) and searched for evidence of (epi)genet-
ic alterations and/or deregulation of expression of their human 
orthologues in the melanoma clinical samples from the TCGA 
cohort (see Methods for a detailed description of the pipeline). 
1250 orthologues exhibited (focal or broad) CN loss with signifi-
cant association between CN and RNA abundance (FDR ≤ 0.01). 
Table 1. Comparative genomics identifies putative melanoma TSGs
Mouse  
gene
Human  
gene
TSG validated  
in GEMMs  
of melanoma
Significant association 
between RNA abundance  
and patient survival
Reference
Pten PTEN x x 14
Cdkn2b CDKN2B x 31
Nf1 NF1 x 32
Stk11 STK11 (LKB1) x 33
Trp53 TP53 x 19
Fes FES x
Agap2 AGAP2 x
Prdm1 PRDM1 (BLIMP1) x
Bcl10 BCL10 x
Kctd11 KCTD11 x
Nkx3-1 NKX3-1 x
Rap1a RAP1A x
Tnfaip3 TNFAIP3 (A20) x
Apc APC
Brms1 BRMS1
Cadm4 CADM4
Dph1 DPH1 (OVCA1)
Hif3a HIF3A
Kank1 KANK1
Lats1 LATS1
Map2k4 MAP2K4 (MKK4)
Mcc MCC
Men1 MEN1
Ncor1 NCOR1
Pdcd4 PDCD4
Rb1 RB1
Sash1 SASH1
Smad2 SMAD2
Smad4 SMAD4
Sufu SUFU
  
Downloaded from http://www.jci.org on May 5, 2017.   https://doi.org/10.1172/JCI91291
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
6 jci.org
in the vicinity of its transcription start site (TSS) (r = –0.7098, P 
< 0.0001; Supplemental Figure 7B). Importantly, whereas meth-
ylated CpG islands clustered at the 5′ end of FES, CpG islands 
located within the gene body were not methylated (Figure 3A). 
These data indicated that downregulation of FES expression in 
human melanoma may occur through a DNA methylation-de-
pendent mechanism. Given that, in contrast to copy-number loss, 
epigenetic-dependent gene silencing can potentially be reversed 
using epigenetic drugs, we focused our attention on this particular 
putative TSG. Intriguingly, FES encodes a tyrosine kinase, a class 
of proteins best known for their potential protumorigenic, rather 
than tumor-suppressive, functions.
Further inspection of the RNA-seq data from the TCGA cohort 
revealed that FES expression levels were low (below the mean) in 
about 40% of these clinical samples (Figure 3A and Supplemental 
Figure 8A). Notably, there was no bias for any specific common 
Figure 3. FES expression is regulated by promoter methylation in human melanomas. (A) Analysis of FES expression in 474 melanoma clinical sam-
ples from the TCGA cohort. The left panel shows FES mRNA levels ordered from the highest (red) to the lowest (green). The middle panel shows DNA 
methylation profile obtained from 19 array probes located in the CpG sites of FES. The schematic above shows a representation of the FES locus, with 
UTR regions in white and exons in black. CpG positions are shown as red stripes. The right panel depicts the copy number status of the FES locus split into 
cases that show loss (in blue) and gain (in red) and samples in which the CNA status of FES was not assessed (in gray). (B) FES expression in short-term 
melanoma cultures (MM) and 3 normal melanocyte cultures (NM). Upper graph shows expression of FES mRNA levels as determined by RT-qPCR. Values 
are normalized to the mean RNA level of normal melanocytes, which was set to 1. Error bars show mean ± SD (n = 2). The middle panel shows Western blot 
analysis of FES. Actin served as a loading control. The bottom panel shows methylation profile of short-term melanoma cultures and normal melanocytes 
as determined by bisulfite sequencing of 20 CpG sites located at positions ranging from –72 to +115 from the FES′ TSS. BRAFV600E (B) and NRASQ61K,L,R (N) 
mutational status is indicated on top of the sample name. (C) Expression of FES in MM031 cell culture after treatment with demethylating agent decit-
abine or its vehicle. The upper panel shows FES mRNA levels assessed by qRT-PCR. Western blot analysis in the 2 lower panels shows FES protein levels. 
GAPDH served as a loading control.
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mutational event (i.e., BRAF versus NRAS mutations) to occur in 
these selected samples (Supplemental Figure 8B). Interestingly, 
low mRNA abundance significantly correlated with poor progno-
sis (P = 0.0456; Supplemental Figure 8C). To further validate and 
extend these results, we assessed FES mRNA levels by RT-qPCR 
in 8 normal human primary melanocyte cultures (NHME), 12 
short-term melanoma cultures, and 23 melanoma cell lines (38). 
Whereas high levels of FES were detected in NHME cultures, FES 
mRNA levels were lower in most melanoma cultures (Figure 3B, 
Supplemental Figure 7A, and Supplemental Figure 8D). Western 
blotting analysis confirmed that the decrease in mRNA levels was 
correlated with a concomitant decrease in FES protein levels (Fig-
ure 3B and Supplemental Figure 8E).
To further confirm this finding, the CpG DNA methylation 
status of the region flanking the FES′ TSS was assessed by bisul-
fite sequencing in primary melanocytes and short-term (Figure 3B) 
and long-term (Supplemental Figure 8E) melanoma cultures. Lit-
tle to no methylation was detected in primary melanocytes, which 
expressed high levels of FES. In contrast, the levels of CpG DNA 
methylation in human melanoma cultures were generally higher 
than in melanocytes and largely inversely correlated with FES mRNA 
abundance. Moreover, FES expression could be restored upon 
exposure of melanoma cells to 5-aza-2′-deoxycytidine (5-aza-dC, 
decitabine), which inhibits CpG methylation (Figure 3C).
Notably, in silico inspection of the human melanoma TCGA data 
indicated that the FES locus was not more frequently targeted by 
mutations than occurring by chance (MutSig 2CV, q = 1). Only a few 
missense mutations were identified (8 mutations from 278 patients 
from the TCGA cohort; 2.9%), and although 2 of these mutations 
affected residues located in the kinase domain (Supplemental Fig-
ure 8F), these residues were not conserved and the mutations are not 
predicted to affect the kinase activity, according to Meta-SNP (http://
snps.biofold.org/meta-snp/) and PredictSNP2 (http://loschmidt.
chemi.muni.cz/predictsnp2/; ref. 39). Together, these data indicate 
that cytosine methylation, rather than inactivating mutations, is a 
common mechanism of FES silencing in human melanoma.
The observation that FES is expressed in NHME was both 
new and, to some extent, surprising. Importantly, FES protein 
expression was readily detected by IHC in melanocytes from nor-
mal human skin, ruling out the possibility that the high levels of 
expression detected in NHME cultures was an artifact of in vitro 
culturing. Whereas FES expression was also elevated in all benign 
nevi examined, FES immunoreactivity varied from high/medium 
(FES positive) to very low/undetectable (FES negative) in various 
cutaneous melanoma samples included in an initial survey study 
(Figure 4A). Interestingly, in FES-positive samples, there was a 
tendency toward decreased immunoreactivity in the dermal inva-
sive melanoma cells compared with the noninvasive epidermal 
component (Figure 4A). Consistently, an anticorrelation between 
FES mRNA levels and thickness according to Breslow (https://
xenabrowser.net) was observed in the TCGA clinical samples 
(Supplemental Figure 8G).
To further survey FES protein expression in a larger cohort 
of biospecimens, 2 tissue micro-arrays (TMAs) from UZ Leuven 
(40) and 3 commercially available TMAs (ME1004d + ME2081 
+ ME2082b) containing collectively 27 benign nevi, 219 primary 
melanomas, and 221 metastatic melanomas were examined. The 
majority of nevi (85%) were positive for FES, whereas 39% of pri-
mary melanomas and 23% of metastatic melanomas expressed 
very low/undetectable FES levels. Two of the TMAs were anno-
tated with survival outcomes and comprised 687 evaluable cores, 
corresponding to 176 melanomas, 40 of which were primary and 
136 metastatic. Of the evaluable melanomas, 138 melanomas 
(75%) were positive (high/medium) and 38 (21%) were negative 
(low/undetectable) for FES. A statistically meaningful association 
was observed between FES protein levels and survival. Patients 
with low/undetectable levels of FES showed a significantly shorter 
survival than patients with high/medium FES protein expression 
(log-rank test: P = 0.0054, Figure 4B).
Importantly, whereas restoration of FES expression in 2 
FES-negative melanoma cell lines (MeWo and 501 Mel) only min-
imally affected the proliferative capacity of these cells in optimal 
growth conditions, it did drastically decrease the ability of MeWo 
(and to a lesser extent 501 Mel) to form colonies when plated at 
low density and to support anchorage-independent growth in soft 
agar (Figure 5, A–C, and Supplemental Figure 9). Moreover, FES 
expression dramatically decreased the ability of MeWo to form 
tumors when injected into immune-compromised mice (Figure 
5D). Importantly, FES-dependent growth inhibition was depen-
dent on the integrity of its kinase domain, as reintroduction of 
Figure 4. Low FES expression defines a subset of human melanoma with poor prognosis. (A) Representative pictures of FES staining in human cutane-
ous melanoma samples. Left panel shows FES staining in normal human skin; the inset shows a zoom-in view of a melanocyte residing in the basal layer 
of the epidermis. The three panels on the right show representative photographs of FES-positive and FES-negative melanoma cases. The photograph on 
the far right depicts the difference in the intensity of FES staining within melanoma. The epidermal layer (E) showed more intense staining compared with 
the dermal skin layer (D). Scale bars: 100 μm. (B) Kaplan-Meier curve of FES-positive versus FES-negative cases determined from FES staining on a tissue 
microarray containing 176 human metastatic melanoma samples. The survival time represents the time from the diagnosis of primary melanoma until the 
melanoma-related death of the patient. Statistical significance was determined by the Mantel-Cox test (α = 5.000%).
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shown). A significant increase in the proliferation index and in 
the number of cells positive for the cell proliferation marker Ki67 
in BrafCA/+ Ptenfl/fl Fes KO, as compared with WT, tumors (Figure 
6, E and F) indicated that Fes loss drives tumor progression, at 
least in part, by promoting an increase in melanoma cell pro-
liferation. Together, these data establish Fes as a suppressor of 
BRAFV600E-driven melanomagenesis in mice.
To gain insights into the molecular mechanisms underlying 
Fes’ tumor-suppressor function, we profiled the transcriptome of 
Tyr-CreERT2/° BrafCA/+ Ptenfl/fl Fes+/+ and Tyr-CreERT2/° BrafCA/+ Ptenfl/fl 
Fes–/– melanoma lesions (n = 5 per group) by RNA-seq. Differen-
tial gene expression analysis showed enrichment for signatures 
associated with increased Wnt signaling (P = 3.77 × 10–3) and cell 
proliferation (P = 7.51 × 10–3) among the upregulated genes and 
immune response among the downregulated genes (P = 3.51 × 10–
27; Figure 7, A and B, and Supplemental Table 8). Previous reports 
indicated that active β-catenin signaling in melanoma is associat-
ed with increased cell proliferation and more aggressive disease 
(17). Moreover, tumor-intrinsic β-catenin activation dominantly 
excludes T cell infiltration into the melanoma tumor microenvi-
ronment (43). An increase in β-catenin signaling may therefore, 
at least partly, drive both the increased cell proliferation gene 
expression signature and, indirectly, the downregulation of genes 
linked to immune response.
a FES kinase–dead mutant (K590E; ref. 41) did not affect the 
growth of MeWo melanoma cells (Figure 5, E–G). Together, these 
observations are consistent with a tumor-suppressor role for FES 
in human melanoma that depends on its kinase activity.
Fes deficiency promotes the progression of BRAFV600E-induced 
murine melanoma. Together, the above data raise the possibil-
ity that FES may function as a tumor suppressor in melanoma. 
In order to directly test this possibility, we combined a Fes-null 
allele (42) with the Tyr-CreERT2 BrafCA/+ alleles. The BrafCA/+ allele 
enables tamoxifen-inducible expression of the constitutively 
active BRAFV600E mutation. We initiated tumorigenesis in Tyr-
CreERT2/° BrafCA/+ Ptenfl/fl Fes+/+ (Fes WT) and Tyr-CreERT2/° BrafCA/+ 
Ptenfl/fl Fes–/– (Fes KO) animals by tamoxifen exposure on the back 
skin or tail. Macroscopic examination of the melanoma lesions 
after tumor induction revealed acceleration of tumor growth on 
the Fes- deficient background (Figure 6, A and B, and Supplemen-
tal Figure 10, A and B). Accordingly, Fes loss led to a significant 
reduction in tumor latency and significantly reduced overall 
survival (Figure 6C). Notably, Fes loss also led to a significant 
decrease in tumor latency and overall survival on the BrafCA/+ 
Ink4a–/– background, which is far less penetrant than the BrafCA/+ 
Ptenfl/fl background (Figure 6D). Histological analyses confirmed 
that the dissected tumors were of melanocytic origin and stained 
positive for the melanoma marker S100 (Figure 6E and data not 
Figure 5. FES reexpression decreases cell proliferation in vitro and in vivo in a kinase-dependent manner. (A) Western blot analysis of FES in MeWo cell line 
with overexpression of FES. Actin served as a loading control. (B) Clonogenic assay of MeWo cells with and without expression of exogenous FES. Error bars 
indicate mean ± SEM (n = 4 biological replicates per group). (C) Soft agar assay of MeWo cells with and without expression of exogenous FES. Error bars indi-
cate mean ± SEM (n = 3 biological replicates per group). (D) Mice (n = 9) were injected with 1 × 106 MeWo cells to the left or MeWo cells expressing exogenous 
FES to the right side of the body. The tumor volume was measured every 3 to 4 days up to day 24. Error bars indicate mean ± SEM (n = 9 biological replicates 
per group). (E) Schematic indicating the location of the FES kinase-dead mutation. F-B, F-BAR domain. (F) Western blot analysis of doxycycline-induced 
expression of WT or mutant FES in MeWo cell line. Vinculin served as a loading control. (G) Clonogenic assay of MeWo cells expressing WT or mutant FES. 
Quantification of the assay measured as the percentage of area covered is shown in the graph on the right. Error bars indicate mean ± SEM (n = 3 biological 
replicates per group). Statistical significance was determined by unpaired 2-sided t test (B, G) and 2-way ANOVA (C, D).
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target genes, such as Trp1, Trp2, and Tyr, were observed in Fes KO 
melanoma lesions (Supplemental Figure 10, D and E). An increase 
in the cell differentiation gene expression signature (P = 5.82 × 10–3) 
was also apparent in the Fes KO lesions (Figure 7A). Finally, consistent 
with an increase in expression of melanocytic pigmentation genes, 
Fes KO melanoma lesions were more pigmented than their Fes WT 
counterparts (Supplemental Figure 10F and data not shown). Togeth-
er, these results establish a clear genetic link between FES and mela-
noma progression and indicate that FES dampens tumor progression, 
at least in part, by decreasing β-catenin activation.
Discussion
Our study provides what we believe is the first comprehensive 
analysis of the genomic landscape of the widely used BRAFV600E- 
and/or NRASQ61K-driven mouse models of melanoma. This anal-
ysis provides important insights into the biology of these geneti-
Total β-catenin protein levels were not significantly higher 
in Fes KO tumors. Similarly, mRNA expression levels of the gene 
encoding β-catenin (Ctnnb1) were not affected by Fes loss (Supple-
mental Figure 10C). Consistent with elevated β-catenin signaling, 
however, a clear accumulation of nuclear β-catenin was observed 
in Fes-deficient lesions (Figure 7, C–F). In contrast, levels of p-Erk, 
p-Akt (Ser-473), and p-STAT3 were comparable in Fes WT and KO 
melanoma lesions, indicating that MAPK, PI3K, and JAK-STAT sig-
naling were, by and large, not affected by Fes loss (data not shown).
Expression of many melanocytic pigmentation genes is con-
trolled by the melanocyte-specific isoform of melanogenesis-asso-
ciated transcription factor (MITF), MITF-M, which is a downstream 
target of β-catenin signaling (44, 45). Enhanced β-catenin signaling 
in melanoma is therefore often accompanied by an MITF-M–depen-
dent increase in melanocytic differentiation markers (17). Consis-
tently, increased MITF-M protein levels and upregulation of MITF 
Figure 6. Fes loss accelerates progression of BRAFV600E-driven, PTEN-deficient, or INK4a-deficient melanoma. (A) Representative photographs of Tyr-CreERT2 
BrafCA/+ Ptenfl/fl mice either Fes+/+ or Fes–/– at days 27 and 41 after topical treatment of the back skin with 5 mM 4-HT. (B) Box plot shows the tumor volume mea-
sured at day 40 after 4-HT exposure of Fes+/+ (n = 13) or Fes–/– (n = 10). (C) Kaplan-Meier analysis of Fes+/+ (n = 13) and Fes–/– (n = 15) mice on a Tyr-CreERT2 BrafCA/+ 
Ptenfl/fl background. (D) Kaplan-Meier analysis of Fes+/+ (n = 7) and Fes–/– (n = 18) mice on a Tyr-CreERT2 BrafCA/+ Ink4a–/– background. (E) IHC of S100 melanoma and 
Ki67 proliferation markers in Tyr-CreERT2 BrafCA/+ Ptenfl/fl melanomas that were WT or KO for Fes. Scale bars: 100 μm. (F) Proliferative index of Fes+/+ (n = 8) or Fes–/– 
(n = 10) melanomas from E determined by counting Ki67+ nuclei within the tumor. Statistical significance was determined using the Mann-Whitney U test (B and 
F) or the Mantel-Cox test (C and D). Box boundaries, 25th and 75th percentiles; whiskers, minimum and maximum; center line, median (B and F).
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The majority of genomic alterations observed in the mouse 
lesions were focal and broad deletions, which are likely associat-
ed with loss of TSG function. This is only partly surprising, since 
the lesions were engineered to already express either one of the 
two most common melanoma oncogenes, namely BRAFV600E and 
NRASQ61K. Focusing on the recurrently deleted regions, a list of 
30 putative melanoma tumor suppressors has been established 
through comparative oncogenomics analysis. A striking observa-
tion is that a majority of these genes are highly functionally linked, 
which further supports the notion that melanoma therapies should 
be directed against signaling pathways themselves rather than 
individually mutated genes and provide a rational explanation as 
to why only transient therapeutic responses to BRAFV600E inhibi-
tors are observed in BRAF-mutated melanoma patients (12).
All melanoma TSGs validated genetically using mouse mod-
els, namely Pten, Cdkn2b, Nf1, Trp53, and Stk11 (also known as 
cally engineered melanomas. Moreover, because of the reduced 
mutational noise compared with human melanoma, comparative 
genome analysis of these mouse lesions with their human coun-
terparts and integration of these data with publically available 
epigenomic and transcriptomic data from human melanoma clin-
ical samples allowed the identification of what we believe are pre-
viously unknown drivers of melanoma progression.
Our analysis reveals highly molded somatic melanoma mouse 
genomes with a very low somatic point mutation frequency and 
much fewer CNAs and structural rearrangements than their 
human counterparts. Notably, as previously observed in other 
p53-deficient mouse cancers, including lung (27), lymphoma (46), 
or nonmelanoma skin cancers (23), functional inactivation of p53 
led to dramatic chromosomal rearrangements. Inactivation of p53 
can therefore be used as a genetic trick to recapitulate the dramatic 
chromosomal rearrangements seen in human melanoma.
Figure 7. Wnt signaling is exacerbated in 
Fes-null mouse melanomas. (A) Heat map 
showing differential gene expression in mela-
noma lesions from Tyr-CreERT2 BrafCA/+ Ptenfl/fl  
mice either Fes+/+ or Fes–/– (n = 5 biological 
replicates per group). The 198 downregulated 
genes and the 96 upregulated genes (P < 0.05) 
are indicated in blue and red, respectively.  
(B) Network of genes upregulated in Fes–/– 
tumors and involved in regulation of cell prolif-
eration. Direct β-catenin targets are indicated 
by arrows. (C) Western blot analysis of FES, 
β-catenin, and E-cadherin protein levels in 
Fes+/+ or Fes–/– melanoma lesions. Vinculin 
and GAPDH served as loading controls. (D) 
Quantification of β-catenin levels from C. (E) 
IHC of β-catenin in Fes+/+ and Fes–/– melano-
mas. Scale bars: 100 μm. (F) Quantification 
of β-catenin–positive nuclei in Fes+/+ (n = 8) 
and Fes–/– (n = 8) melanomas. Box boundaries, 
25th and 75th percentiles; whiskers, minimum 
and maximum; center line, median (D and F). 
Statistical significance was determined using 
the Mann-Whitney U test (F).
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analysis indeed indicated that FES may function as a Wnt path-
way inhibitor and, consistently, an increase in nuclear β-catenin 
levels was observed in Fes-deficient BRAFV600E-driven tumors. 
This observation is in line with the previously reported cooperativ-
ity between stabilized β-catenin and BRAFV600E in the formation 
of aggressive mouse melanomas (17). Note that since stabilized 
β-catenin also cooperates with activated NRAS in mouse melano-
ma development (61), it is possible and may be likely that loss of 
Fes may also accelerate melanomagenesis on the NRAS-mutant 
background; this remains to be tested experimentally. We also 
show herein that ectopic FES expression severely compromised 
the in vitro and in vivo growth of MeWo cells, which express WT 
β-catenin. In contrast, FES-induced growth inhibition was far 
less dramatic in 501 Mel cells, which carry a β-catenin-stabilizing 
mutation (59). Taken together, these data indicate that FES exerts 
its tumor-suppression function, at least partly, as an inhibitor of 
canonical WNT–β-catenin signaling. Although the molecular 
mechanism underlying FES-dependent inhibition of WNT sig-
naling remains to be fully elucidated, our data indicate that FES 
modulates β-catenin cellular localization, rather than its stability, 
in a manner that depends on its kinase activity. Additional work is 
needed to determine whether FES affects β-catenin nuclear trans-
location indirectly or directly, by phosphorylating β-catenin itself.
Recurrent focal and broad amplifications in the mouse mela-
noma genomes were not as common as recurrent deletions. Broad 
amplifications of chromosome 6 were nevertheless significantly 
(q ≤ 0.25) recurrent in both BRAFV600E- and NRASQ61K-driven mel-
anomas. In addition, 3 distinct recurrent focal amplifications, all 
located on chromosome 6, were also observed in NRASQ61K-driven 
melanomas. Notably, one of them contained the Braf gene, which 
indicates that increased Braf expression may promote a growth 
advantage to NRASQ61K-driven melanoma lesions. Interestingly, 
one of these recurrent amplifications contained Smo, a key signal 
transducer of Hh signaling. This observation raises the possibility 
that increased Hh signaling may contribute to melanomagenesis. 
Consistent with this possibility, several components of Hh signal-
ing pathway, including the well-established negative regulators 
Sufu and Kctd11, are among the 30 melanoma TSGs we identified. 
To date, only few studies have tentatively implicated Hh signaling 
in melanoma (62–64). Our work therefore warrants further dissec-
tion of the role of Hh signaling in melanomagenesis and leads us 
to entertain the possibility that Hh inhibitors should be considered 
in the context of (combination) melanoma targeted therapies.
This work provides a rich resource of candidate genes involved 
in melanoma progression in addition to a list of pathways and bio-
logical processes with potential clinical importance in the treat-
ment of human melanoma.
Methods
Transgenic mice. The Tyr-CreERT2/°, BrafCA/+, BrafLSL–V600E/+, Ink4a–/–, 
Ptenfl/fl, Tyr-NrasQ61K/°, Trp53–/–, Trp53fl/fl, Cdkn2a–/–, R26RLSL–eYFP/+, and 
Fes–/– mouse lines and strategies used for genotyping these mice were 
described previously (13, 21, 22, 42, 65–71). The various cohorts of 
compound mice were on mixed genetic backgrounds consisting of 
more than 85% C57BL/6J and, to a lesser extent, 129SvJ and FVB. The 
full list of samples collected from the compound mice and their genet-
ic background can be found in Supplemental Table 1.
Lkb1), and several other genes previously linked to melanoma 
(i.e., Apc), were present in this list. Importantly, about 20 genes 
that have not been causally linked to melanoma were also iden-
tified, half of which have potential value in predicting human 
patient survival outcomes. This analysis therefore provides a rich 
resource of clinically relevant melanoma genes and a framework 
for further genomic validation of these genes as bona fide melano-
ma TSGs. In the context of the present study, we chose to validate 
one of these genes, Fes, by compound deletion in the autochtho-
nous BRAFV600E-driven mouse melanoma model. Importantly, we 
provide genetic evidence that inactivation of Fes promotes mel-
anoma progression and decreases survival of animals bearing 
BRAFV600E-expressing melanoma lesions. Together, these data 
illustrate the potential of this comparative and integrative genom-
ic effort to identify acquired drivers of progression and dissect 
stepwise tumorigenesis.
FES was first described as the product of a viral oncogene 
(47) and has been implicated in growth and survival signaling in 
leukemia cell lines driven by oncogenic KIT and FLT3 receptors 
(48, 49). Despite these initial observations, there is to date no 
clear evidence that FES functions as an oncoprotein in human 
cancer. In contrast, large-scale sequencing of the tyrosine kinome 
in colorectal tumors identified FES as one of a few mutated genes 
(50). Although not conclusive, the loss-of-function nature of these 
mutations and in vitro assays using colorectal cancer cell lines 
raised the possibility that FES may instead function as a potential 
tumor suppressor (41, 51). Herein we provide clear evidence that 
FES functions as a TSG in both human and mouse melanoma. 
Consistent with this finding, an old study reported low levels of 
FES in a few human melanoma cell lines (52).
Protein kinases are often upregulated in cancer and are attrac-
tive therapeutic targets. However, protein kinases exert pleiotro-
pic functions, such as increased survival, progression of the cell 
cycle, differentiation, adherence, or migration, that are dependent 
on the tissue and molecular environment of the cells. Ultimate-
ly, this implies a context-dependent functional role of specific 
kinases in cancer, i.e., oncogene or TSG function (53). Our data 
provide an additional example of a tyrosine kinase that acts as a 
tumor suppressor. Importantly, kinase inhibitors are now wide-
ly used in the clinic, including for the treatment of melanoma. 
Despite assertions on selectivity, most available inhibitors target 
multiple protein kinases in addition to the intended target (54). 
Considering the increasing list of kinases with putative TSG func-
tion, a comprehensive characterization of protein kinase function 
and kinase inhibitor selectivity profiling is essential for the proper 
management of these drugs in the clinic. Of note, FES is inhibited 
by ALK inhibitors (55) and several FDA-approved drugs such as 
the CDK1/2 inhibitor III, sunitinib, or bosutinib (56).
Whereas nuclear β-catenin, which reflects canonical Wnt 
pathway activation, is present in about 30% of human melanoma 
specimens (57), β-catenin-stabilizing mutations are only found 
in about 5% of the cases (43, 58, 59). The molecular mechanisms 
underlying such a frequent dysregulation of β-catenin localization 
and activation of function remain unclear (60). Interestingly, our 
data raise the possibility that epigenetic downregulation of FES 
transcription is one key mechanism that contributes to Wnt sig-
naling activation in β-catenin WT melanomas. Our transcriptomic 
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renewed every 3 days. After 6 or 9 days, cells were collected for 
RT-PCR and Western blot analysis.
For FES reexpression experiments, control or Fes cDNA LXSN 
retroviral vectors were transfected in Phoenix A cells using Lipofect-
amine 2000 (Thermo Scientific). Culture supernatants containing 
the retroviruses were used to infect melanoma cells in the presence 
of polybrene (Sigma-Aldrich) at 8 μg/ml overnight. After 2 rounds of 
infection, cells were selected using Geneticin (Thermo Scientific) at 1 
mg/ml. For the clonogenic assay, 501 Mel or MeWo cells were seeded 
at low density in 60-mm culture plates in 3 ml media and grown for 8 
to 10 days. Colonies were then fixed in 4% paraformaldehyde (Ther-
mo Scientific), stained with 0.05% crystal violet, and counted. For 
the soft agar assay, cells were seeded in 12-well culture plates in 1 ml 
of supplemented DMEM containing 0.3% agar (Thermo Scientific). 
After 14 days, cells were stained with 0.002% crystal violet (Sigma- 
Aldrich) and colonies were scored using ImageJ software.
For the doxycycline-inducible expression of WT and kinase-
dead mutant FES, MeWo cells were transduced with the lentivirus 
carrying the vector for TetR (FUGW plasmid with GFP replaced by 
TetR-T2A-NeomycinR) and selected with Geneticin (InvivoGen) at 1 
mg/ml. Selected cells were transduced with lentivirus carrying a doxy-
cycline-inducible conditional vector for FESWT or FESK590E and selected 
with puromycin (Sigma-Aldrich). The conditional vectors were made by 
Gateway-recombining pENTRY-FESWT/K590E vectors (41) with a pLEN-
TI CMV/TO Puro DEST (Addgene, vector #17293). For the clonogenic 
assay, cells were plated onto 6-well plates at a density of 5,000 cells and 
incubated with doxycycline to induce the expression of FES. After 10 to 
11 days, colonies were fixed and stained in a solution of 1% crystal violet 
in 35% methanol for 15 minutes and scored using ImageJ software.
MeWo cells injections. MeWo cells (1 million) were injected in 150 
μl of 0.9% NaCl subcutaneously into nude mice (Janvier). Control and 
FES MeWo transfected cells were injected in the opposite flanks of 
mice. Tumor growth was monitored twice a week until week 24.
Bisulfite sequencing. Genomic DNA was extracted using the 
QIAamp DNA Mini Kit (QIAGEN). For bisulfite conversion, we used 
the EZ DNA Methylation Gold Kit (Proteigene) according to the man-
ufacturer’s instructions. Then a first PCR amplification was done 
(F-GTTGGGTTATTTTTTTTCGGTT and R-TAAATAAATCTCTA-
ACCCTC), followed by a nested PCR (F-GGAGTAGGGGGGTTGG-
TAGG and R-CCTACTCTACCCCTACCTACC). PCR products were 
sequenced using the BigDye Terminator v1.1 Cycle Sequencing Kit 
(Thermo Scientific) on an Applied Biosystems 3130 DNA Analyzer.
Lysates and Western blotting. Cultured cells were lysed at 4°C in 
HNTG buffer (50 mM Hepes, pH 7.0, 150 mM NaCl, 1% Triton X-100, 
10% glycerol, 1 mM EGTA, 1.5 mM MgCl2) supplemented with pro-
tease inhibitor cocktail (Roche) and orthovanadate (Sigma-Aldrich). 
Protein concentrations were assessed using the Bradford protein assay 
(Bio-Rad). Following SDS-PAGE, lysates were transferred on PVDF 
membranes (Millipore). Immunoblotting was performed using rabbit 
polyclonal anti-ERK2 (Santa Cruz Biotechnology Inc.), mouse mono-
clonal anti–β-actin (Sigma-Aldrich), and rat monoclonal anti-Fes (Cal-
biochem) antibodies and SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific).
Tissue samples were additionally homogenized with Precellys 
Homogenizer (Bertin Technologies) in protein lysis buffer (25 mM 
HEPES, pH 7.5, 0.3 M NaCl, 1.5 mM MgCl2, 2 mM EDTA, 2 mM EGTA, 
1 mM DTT, 1% Triton X-100, 10% glycerol, phosphatase/protease 
Activation of the Tyr-CreERT2 locus. Topical administration of 
4-hydroxytamoxifen (4-HT) was conducted by preparing a 50 mg/ml 
solution (130 mM) of 4-HT (70% Z-isomer, Sigma-Aldrich) in DMSO. 
For localized melanoma induction on the back, 3- to 4-week-old mice 
were anesthetized and depilated on a 2-cm2 patch of skin on the back 
with a combination of gum rosin and beeswax (Sigma-Aldrich). After 
the area was dried and cleaned, 1 μl of 5 mM 4-HT in ethanol vehi-
cle was applied using a pipette. For distal tail inductions, 4 μl of 130 
mM 4-HT was applied on the middle part of the tail (4 cm long) and 
wrapped by surgery tape to prevent the spread of 4-HT. The mice were 
evaluated weekly for tumor appearance and progression and mea-
sured with a caliper. The volume was calculated using the following 
formula: V = (length × width × height)/2. Mice were killed as soon 
as the tumors reached 15 mm3 or sooner if they were suffering from 
tumor burden. Tumors and organs were snap-frozen in liquid nitrogen 
for further analysis or fixed in 4% paraformaldehyde, processed, and 
embedded in paraffin for histological studies.
Histology and IHC. Tissues were fixed overnight in 4% parafor-
maldehyde, dehydrated, paraffin embedded, sectioned (5 μm), and 
stained with H&E. For IHC, slides were stained with antibodies against 
S100 (Z0311; 1:300; Dako) and Ki67 (RM-9106-S; 1:200; Thermo-
Scientific) and β-catenin (#9582; 1:1000; Cell Signaling Technology). 
Stainings were realized in the Ventana automated stainer from Roche 
using EnVision+ HRP reagent and DAB (DAB Peroxidase Substrate 
Kit, SK-4100; Vector Laboratories) for revelation. To assess prolifera-
tive index, Ki67-positive and -negative nuclei were counted in at least 
3 microscopic fields randomly selected from different regions of each 
tumor section by applying a digital image analysis algorithm created 
on the ImageJ software platform (NIH). Proliferative index was then 
expressed as the ratio between positive and total numbers of nuclei. 
The percentages of β-catenin–positive nuclei were counted using 
ImageJ within 30 different fields from 8 different tumors per group.
IHC for FES was performed on formalin-fixed, paraffin-embedded 
material of benign nevi, primary and metastatic human melanomas, 
and TMA cohorts on the Leica BOND-MAX automatic immunostainer 
(Leica Microsystems) using primary antibody HPA001376 (1/100 dilu-
tion; Sigma-Aldrich). Antigen retrieval was performed onboard using 
a citrate-based buffer (Bond Epitope Retrieval Solution 1, pH 6.0; Lei-
ca) according to the manufacturer’s instructions. Alkaline phosphatase 
activity was detected with Bond Polymer Refine Red Detection (Leica) 
as substrate, resulting in pink/red immunoreactivity. TMAs stained for 
FES were scored semiquantitatively by two researchers (FES negative, 
cores with melanoma cells showing low-intensity to undetectable cyto-
plasmic immunoreactivity; FES positive, cores with melanoma cells 
showing high- to medium-intensity cytoplasmic immunoreactivity; see 
Figure 4A for representative cores). Melanoma-specific survival was 
defined as the interval from diagnosis of the primary tumor to death 
from melanoma or date of last follow-up.
Cell culture. Melanoma cell lines (ATCC; ref. 72, 73) and Phoe-
nix A cells (ATCC) were maintained in DMEM (Thermo Scientific) 
supplemented with 10% fetal bovine serum (Eurobio) and 2 mM 
glutamine (Thermo Scientific). Short-term melanoma cultures were 
maintained in Ham’s F10 Nutrient Mix (Thermo Scientific) supple-
mented with 10% FBS and 4 mM glutamine. Cells were cultured in a 
37 °C and 5% CO2 incubator.
For the decitabine experiment, a final concentration of 0.5 μM 
decitabine (Sigma-Aldrich) was added to the cells and media were 
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24). DNA samples from NrasQ61K Cdkn2a–/– melanomas (n = 5) were 
obtained from cells after tumor dissociation followed by initial expan-
sion in nude mice and were provided by Lukas Sommer (University of 
Zurich, Zurich, Switzerland). Whole-genome DNA libraries were pre-
pared using the KAPA HTP Library Preparation Kit (Kapa Biosystems) 
and either used for low- coverage whole-genome sequencing directly or 
further prepared for use in exome sequencing.
Exome sequencing, variant calling, validation, and scoring. In order 
to perform exome capture, the amplified DNA libraries were hybrid-
ized to a complete set of biotinylated long oligonucleotide probes 
using the SeqCap EZ Library Kit (Roche NimbleGen) for approxi-
mately 65 hours. After this, the exome-enriched libraries were washed 
and recovered using capture beads. The libraries were sequenced on 
a HiSeq2000 (Illumina) sequencing platform. An existing, in-house–
developed pipeline for the analysis and annotation of somatic muta-
tions in these samples was used (described below). Raw reads were 
mapped to the mouse reference genome (GRCm38/mm10) using 
the Burrows-Wheeler Aligner (v0.5.8a; ref. 75). Duplicate reads were 
marked using Picard (v1.43). We obtained an average coverage of 62× 
with on average 94% of the exome covered at least 10×. The Genome 
Analysis Toolkit (GATK; v2.1-13; Broad Institute; ref. 76) was used to 
recalibrate base qualities and local realignment around indels. Vari-
ant calling was performed using GATK’s Unified Genotyper (GATK, 
v2.1-13). Small insertions and deletions of less than 50 bp were identi-
fied using Dindel (v1.01; ref. 77). Variants were functionally annotated 
using ANNOVAR (v2013Jun21; ref. 78). Somatic variant identification 
was performed by comparing tumor genomes with variants present 
either in the matching or combined normal samples. SNPs and indels 
reported by the Mouse Genome Project of the Sanger Institute were 
removed as well, according to the mixed genetic background of our 
mice. Mutations that were represented with more than 5% alterna-
tive reads in the control samples or mutations represented with less 
than 10% alternative reads in tumor samples were discarded. Result-
ing variants were manually inspected using the Integrative Genomics 
Viewer (IGV; v2.3.67; Broad Institute) in order to omit the variants in 
regions with low mapping quality and variants present but not called 
in the germline samples. Selected mutations were validated using 
Sequenom MassARRAY (Sequenom Inc.) genotyping according to the 
manufacturer’s instructions. Primers were designed with MassARRAY 
Assay Design software v3.1. Automated genotyping calls were generat-
ed with MassARRAY RTTM software v4.0 and were validated by man-
ual review of the raw mass spectra. Raw data were deposited in the 
ArrayExpress database (www.ebi.ac.uk/arrayexpress; E-MTAB-4917).
CNA analysis. For the analysis of CNAs, we performed low- 
coverage whole-genome sequencing of all 70 mouse melanomas 
on the HiSeq2500 (Illumina) sequencing platform. The sequenc-
ing reads were mapped to the reference genome (GRCm38/mm10) 
using the Burrows-Wheeler Aligner (v0.5.8a). The duplicate reads 
were removed using Picard (v1.43). After this, the mapped reads 
were binned in 30-kb windows and corrected for genomic waves 
using the PennCNV software package (79). The read counts per bin 
were transformed into logR values, and the data were segmented 
using ASCAT (80). logR values above 0.1 or below –0.1 were con-
sidered as amplified or deleted, respectively. The recurrent CNAs 
were identified using the GISTIC 2.0 tool (81). The control samples 
(n = 9) were used to filter out nonsomatic aberrations. Raw data 
were deposited in the ArrayExpress database (E-MTAB-4921).
inhibitor cocktail); the extracts were incubated on ice for 15 minutes 
and centrifuged for 15 minutes in 4°C at 20,000 g. Protein concentra-
tion was measured by Bradford quantification and run on 4% to 12% 
NuPAGE Novex Bis-Tris Gels (Thermo Fisher Scientific). Membrane 
blocking (5% milk in TBS, 0.2%Tween-20) was followed by incuba-
tion with the appropriate primary antibodies and HRP-conjugated sec-
ondary antibody (Cell Signaling Technology). Proteins were detected 
by ECL and Western blotting (Thermo Scientific). Antibodies used are 
listed in Supplemental Table 9.
RT-qPCR. To extract RNA, samples were lysed in QIAzol (QIA-
GEN). Tumor samples were additionally homogenized with a Pre-
cellys Homogenizer (Bertin Technologies). RNA extraction was per-
formed with the mRNeasy Mini Kit according to the manufacturer’s 
instructions (QIAGEN). RNA was quantified using a NanoDrop 1000 
(Thermo Scientific), and 2,000 ng was reverse transcribed with the 
High-Capacity cDNA Reverse Transcription Kit (Life Technologies). 
The results shown in Figure 3B were obtained by RT-qPCR reaction on 
an Applied Biosystems 7500 Fast Real-Time PCR System using SYBR 
Green PCR Master Mix (Thermo Scientific). Threshold cycle (Ct) val-
ues for Fes were normalized to housekeeping gene using the 2ΔCt for-
mula. The results shown in Supplemental Figure 4A and Supplemental 
Figure 10, C and E, were obtained by RT-qPCR reaction on a Roche 
LightCycler 384 (Life Technologies) using Fast SYBR Green Master 
Mix (Life Technologies). Data were processed with qbase+ 2.6 soft-
ware (Biogazelle) using a normalization method with a minimum of 
2 reference genes. RT-qPCR primers are listed in Supplemental Table 
10; the reference genes are indicated in the table as RefGen.
Epidermal whole mount. The epidermal whole mount was per-
formed using an adaptation of a previously described protocol (74). 
Murine tail skin was dissected and spread out on Whatman cellulose 
filter paper. Pieces of murine tail skin were cut and incubated in 20 
mM EDTA in PBS at 37°C for 40 minutes in the dark and subsequently 
washed twice with PBS. The epidermis was mechanically separated 
from the dermis as an intact sheet and was fixed in 4% paraformal-
dehyde for 30 minutes at room temperature in the dark. Pieces of epi-
dermis were rinsed twice with PBS and stored at 4°C or immediately 
processed for antibody staining. For the staining, pieces of epidermis 
were incubated in blocking buffer (1% BSA, 10% donkey serum, 0.2% 
Tween in PBS) for 3 hours at room temperature on a rocking plate (120 
rpm) in the dark. Blocked samples were incubated in primary antibod-
ies diluted in antibody diluent (1% BSA, 0.2% Tween in PBS) overnight 
at 4°C in the dark. The primary antibodies used were anti-melanoma 
gp100 (rabbit, 1:400, Abcam, ab137078). Samples were then washed 3 
times in PBS with 0.2% Tween for 1 hour and incubated in appropriate 
secondary antibodies diluted 1:1000 in antibody diluent for 2 hours at 
room temperature on a rocking plate in the dark. Nuclei were stained 
with DAPI solution (0.5 mg/ml) diluted 1:1,000 in PBS for 20 minutes 
and mounted in VECTASHIELD Antifade Mounting Medium for flu-
orescence (VECTOR).
Tissue collection, DNA extraction, and library preparation. In total, 
70 mouse melanomas were collected for this study. The RNA/DNA 
from these lesions was extracted using the AllPrep RNA/DNA Kit 
(QIAGEN) or the DNeasy Blood & Tissue Kit (QIAGEN) following the 
manufacturer’s instructions. The DNA samples from Trp53LSL–R172H/+ 
BrafLSL–V600E/+ Tyr-CreERT2/° tumors (n = 10) and BrafLSL–V600E/+ Tyr-
CreERT2/° tumors (n = 3) were provided by Richard Marais (Cancer 
Research UK Manchester Institute, Manchester, United Kingdom; ref. 
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Statistics. Group results were compared using unpaired two-sid-
ed t test. The statistical significance between the survival of two 
groups was determined by Mantel-Cox test. Mann-Whitney U-test 
was used when comparing groups with different distributions. Two-
way ANOVA with Šidák method was used for multiple comparison 
analysis. Statistical significance of overlapping gene sets was deter-
mined using hypergeometric distribution test. Significance of cor-
relation was determined using Pearson correlation coefficient test. 
Unless otherwise specified, a P value lower than 0.05 was consid-
ered significant.
Study approval. All procedures involving animals were performed 
in accordance with the guidelines of the IACUC of KU Leuven and 
approved in project application (PO34/2014).
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RNA sequencing. RNA was extracted from Tyr-CreERT2/° BrafCA/+ 
Ptenfl/fl Fes+/+ (Fes WT) and Tyr-CreERT2/° BrafCA/+ Ptenfl/fl Fes–/– (Fes KO) 
(n = 5 per group) melanomas using the RNeasy Mini Kit (QIAGEN) 
following the manufacturer’s instructions. RNA integrity was assessed 
using Bioanalyzer 2100 (Agilent) and RNAs with RIN values of more 
than 7 were used for library preparation. RNA libraries were prepared 
using the Illumina TruSeq Stranded mRNA Sample Prep Kit (protocol 
15031047, Rev E, October 2013). Illumina’s NextSeq library Prep Kit 
(Illumina) was used to prepare the library from 1000 ng of RNA and 
the library quality was monitored on an HS DNA chip (Bioanalyzer, 
Agilent). Sequence libraries of each sample were equimolarly pooled 
and sequenced on a 0.5 run on the Illumina NextSeq 500 platform 
(high output, 75 bp, SR) generating on average 19.8 million reads per 
sample. FastQC was used to assess the quality of the sequenced data. 
Raw reads were mapped to the mouse reference genome (GRCm38/
mm10) using STAR (version 2.51b) resulting in 66.0%–71.2% (13.2 to 
16.6 million) of successfully mapped reads. Reads were assigned to 
Ensembl genes (GRCm38.84) and counted using the Subread package 
(version 1.4.6). Reads were normalized by size factors and log2. Dif-
ferential expression analysis (Fes KO versus Fes WT) was performed 
using DESeq2 (version 1.10.1), and the GO enrichment analysis was 
performed using GOrilla (http://cbl-gorilla.cs.technion.ac.il; accessed 
July 2016). All original microarray data were deposited in the NCBI’s 
Gene Expression Omnibus (GEO GSE83580).
Cross-species comparisons. To analyze the significance of overlap 
between genes located on broad CNAs in human and mouse (NRAS 
driven, Trp53 null) melanomas, we explored the orthologous genes 
(Ensemble; accessed July 2016; total number of 1-to-1 orthologues 
16,728) located on the significantly recurrent broad CNAs in human 
melanomas from the TCGA cohort (Broad Institute; v2016) and mouse 
melanomas from the NRAS-driven, Trp53-null cohort analyzed in this 
study. The comparison between gene expression and patient survival 
was performed by the online tool developed by Phil Cheng (University 
of Zurich, Switzerland; accessed March 2016; ref. 37), selecting only 
the metastatic melanoma samples and the 15th percentile as a cut-off 
for high and low expressers.
For the cross-species comparison of deleted genes, focal and 
broad deletions from all melanoma sample groups were intersected 
with orthologous genes targeted in human melanoma samples (TCGA 
repository). Only genes targeted in human melanomas by significantly 
recurrent deletions, mutations, or promoter hypermethylations were 
used for the analysis. Data (level 4) on CNAs in human melanomas 
were retrieved from the GDAC (Broad Institute TCGA Genome Data 
Analysis Center [2016]: SNP6 copy number analysis [GISTIC2.0]; 
Broad Institute of MIT and Harvard; doi:10.7908/C1445KXQ) per-
formed on 367 samples. Genes targeted by CNAs in human mela-
nomas and significantly positively correlating with the RNA levels 
(q ≤ 0.01) were used for the cross-species comparison. Data on SNAs 
in human melanomas were retrieved from the MutSigCV analysis 
performed on 318 melanoma samples form TCGA (16). The data on 
DNA methylation from 476 human melanoma samples were obtained 
from the Xena repository (methylation 450 k; version 2015-10-26; 
http://xena.ucsc.edu/). CpG probes located 2 kb upstream or 500 bp 
downstream from the gene promoter were analyzed for hypermethyl-
ation. Probes showing more than 70% methylation in more than 10% 
of melanomas while having less than 25% methylation in the skin 
control samples were considered as hypermethylated.
Downloaded from http://www.jci.org on May 5, 2017.   https://doi.org/10.1172/JCI91291
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 5jci.org
Phone: 33.4.86977285; E-mail: sepulveda@inserm.fr. Or to: 
Jean-Christophe Marine, O&N IV Herestraat 49/Box 602, 3000 
Leuven, Belgium. Phone: 32.16.33.03.68; Phone: jeanchristophe.
marine@kuleuven.vib.be.
Address correspondence to: Diether Lambrechts, O&N IV Here-
straat 49/Box 912, 3000 Leuven, Belgium. Phone: 32.16.37.32.09; 
E-mail: diether.lambrechts@kuleuven.vib.be. Or to: Paulo De Sep-
ulveda, CRCM – Inserm, 27 Bd Leï Roure, 13009 Marseille, France. 
 1. Lawrence MS, et al. Mutational heterogeneity in 
cancer and the search for new cancer-associated 
genes. Nature. 2013;499(7457):214–218.
 2. Hanahan D, Weinberg RA. Hallmarks of cancer: 
the next generation. Cell. 2011;144(5):646–674.
 3. Grob JJ, Long GV, Schadendorf D, Flaherty K. 
Disease kinetics for decision-making in advanced 
melanoma: a call for scenario-driven strategy tri-
als. Lancet Oncol. 2015;16(13):e522–e526.
 4. Hodis E, et al. A landscape of driver mutations in 
melanoma. Cell. 2012;150(2):251–263.
 5. Davies H, et al. Mutations of the BRAF gene in 
human cancer. Nature. 2002;417(6892):949–954.
 6. Hocker T, Tsao H. Ultraviolet radiation and 
melanoma: a systematic review and analysis 
of reported sequence variants. Hum Mutat. 
2007;28(6):578–588.
 7. Jakob JA, et al. NRAS mutation status is an inde-
pendent prognostic factor in metastatic melano-
ma. Cancer. 2012;118(16):4014–4023.
 8. Krauthammer M, et al. Exome sequencing iden-
tifies recurrent somatic RAC1 mutations in mela-
noma. Nat Genet. 2012;44(9):1006–1014.
 9. Dhomen N, et al. Oncogenic Braf induces mela-
nocyte senescence and melanoma in mice.  
Cancer Cell. 2009;15(4):294–303.
 10. Cohen C, et al. Mitogen-actived protein kinase 
activation is an early event in melanoma progres-
sion. Clin Cancer Res. 2002;8(12):3728–3733.
 11. Flaherty KT, Hodi FS, Bastian BC. Mutation-driv-
en drug development in melanoma. Curr Opin 
Oncol. 2010;22(3):178–183.
 12. Chapman PB, et al. Improved survival with vemu-
rafenib in melanoma with BRAF V600E muta-
tion. N Engl J Med. 2011;364(26):2507–2516.
 13. Ackermann J, Frutschi M, Kaloulis K, McKee T, 
Trumpp A, Beermann F. Metastasizing melano-
ma formation caused by expression of activated 
N-RasQ61K on an INK4a-deficient background. 
Cancer Res. 2005;65(10):4005–4011.
 14. Dankort D, et al. Braf(V600E) cooperates with 
Pten loss to induce metastatic melanoma. Nat 
Genet. 2009;41(5):544–552.
 15. Shakhova O, et al. Sox10 promotes the formation 
and maintenance of giant congenital naevi and 
melanoma. Nat Cell Biol. 2012;14(8):882–890.
 16. Cancer Genome Atlas Network. Genomic 
Classification of Cutaneous Melanoma. Cell. 
2015;161(7):1681–1696.
 17. Damsky WE, et al. β-catenin signaling controls 
metastasis in Braf-activated Pten-deficient mela-
nomas. Cancer Cell. 2011;20(6):741–754.
 18. Gembarska A, et al. MDM4 is a key therapeu-
tic target in cutaneous melanoma. Nat Med. 
2012;18(8):1239–1247.
 19. Viros A, et al. Ultraviolet radiation accelerates 
BRAF-driven melanomagenesis by targeting 
TP53. Nature. 2014;511(7510):478–482.
 20. Conde-Perez A, et al. A caveolin-dependent 
and PI3K/AKT-independent role of PTEN in 
β-catenin transcriptional activity. Nat Commun. 
2015;6:8093.
 21. Krimpenfort P, Quon KC, Mooi WJ, Loonstra 
A, Berns A. Loss of p16Ink4a confers suscepti-
bility to metastatic melanoma in mice. Nature. 
2001;413(6851):83–86.
 22. Jacks T, et al. Tumor spectrum analysis in 
p53-mutant mice. Curr Biol. 1994;4(1):1–7.
 23. Nassar D, Latil M, Boeckx B, Lambrechts D, 
Blanpain C. Genomic landscape of carcino-
gen-induced and genetically induced mouse 
skin squamous cell carcinoma. Nat Med. 
2015;21(8):946–954.
 24. Olive KP, et al. Mutant p53 gain of function in two 
mouse models of Li-Fraumeni syndrome. Cell. 
2004;119(6):847–860.
 25. Briscoe J, Thérond PP. The mechanisms of 
Hedgehog signalling and its roles in devel-
opment and disease. Nat Rev Mol Cell Biol. 
2013;14(7):416–429.
 26. Ma C, et al. Characterization CSMD1 in a large 
set of primary lung, head and neck, breast 
and skin cancer tissues. Cancer Biol Ther. 
2009;8(10):907–916.
 27. McFadden DG, et al. Genetic and clonal dis-
section of murine small cell lung carcinoma 
progression by genome sequencing. Cell. 
2014;156(6):1298–1311.
 28. Zemach A, McDaniel IE, Silva P, Zilberman 
D. Genome-wide evolutionary analysis 
of eukaryotic DNA methylation. Science. 
2010;328(5980):916–919.
 29. Feng S, et al. Conservation and divergence of meth-
ylation patterning in plants and animals. Proc Natl 
Acad Sci USA. 2010;107(19):8689–8694.
 30. Vogelstein B, Papadopoulos N, Velculescu VE, 
Zhou S, Diaz LA, Kinzler KW. Cancer genome 
landscapes. Science. 2013;339(6127):1546–1558.
 31. McNeal AS, et al. CDKN2B Loss Promotes Pro-
gression from Benign Melanocytic Nevus to Mel-
anoma. Cancer Discov. 2015;5(10):1072–1085.
 32. Maertens O, et al. Elucidating distinct roles 
for NF1 in melanomagenesis. Cancer Discov. 
2013;3(3):338–349.
 33. Liu W, et al. LKB1/STK11 inactivation leads to 
expansion of a prometastatic tumor subpopulation 
in melanoma. Cancer Cell. 2012;21(6):751–764.
 34. Viros A, et al. Ultraviolet radiation accelerates 
BRAF-driven melanomagenesis by targeting 
TP53. Nature. 2014;511(7510):478–482.
 35. Cao J, et al. The E3 ligase APC/C(Cdh1) promotes 
ubiquitylation-mediated proteolysis of PAX3 to 
suppress melanocyte proliferation and melano-
ma growth. Sci Signal. 2015;8(392):ra87.
 36. Jiao J, Fan Y, Zhang Y. Expression and clinico-
pathological significance of microRNA-21 and 
programmed cell death 4 in malignant melano-
ma. J Int Med Res. 2015;43(5):672–678.
 37. Cheng PF, Dummer R, Levesque MP. Data 
mining The Cancer Genome Atlas in the era 
of precision cancer medicine. Swiss Med Wkly. 
2015;145:w14183.
 38. Rambow F, et al. New functional signatures 
for understanding melanoma biology from 
tumor cell lineage-specific analysis. Cell Rep. 
2015;13(4):840–853.
 39. Bendl J, Musil M, Štourač J, Zendulka J, Dam-
borský J, Brezovský J. PredictSNP2: a unified 
platform for accurately evaluating snp effects by 
exploiting the different characteristics of variants 
in distinct genomic regions. PLoS Comput Biol. 
2016;12(5):e1004962.
 40. Winnepenninckx V, et al. Gene expression profil-
ing of primary cutaneous melanoma and clinical 
outcome. J Natl Cancer Inst. 2006;98(7):472–482.
 41. Delfino FJ, Stevenson H, Smithgall TE. A 
growth-suppressive function for the c-fes pro-
tein-tyrosine kinase in colorectal cancer. J Biol 
Chem. 2006;281(13):8829–8835.
 42. Zirngibl RA, Senis Y, Greer PA. Enhanced endo-
toxin sensitivity in fps/fes-null mice with mini-
mal defects in hematopoietic homeostasis. Mol 
Cell Biol. 2002;22(8):2472–2486.
 43. Spranger S, Bao R, Gajewski TF. Melanoma-in-
trinsic β-catenin signalling prevents anti-tumour 
immunity. Nature. 2015;523(7559):231–235.
 44. Widlund HR, et al. Beta-catenin-induced mel-
anoma growth requires the downstream target 
Microphthalmia-associated transcription factor. J 
Cell Biol. 2002;158(6):1079–1087.
 45. Cheli Y, Ohanna M, Ballotti R, Bertolotto C. Fif-
teen-year quest for microphthalmia-associated 
transcription factor target genes. Pigment Cell 
Melanoma Res. 2010;23(1):27–40.
 46. Dudgeon C, et al. The evolution of thymic 
lymphomas in p53 knockout mice. Genes Dev. 
2014;28(23):2613–2620.
 47. Lee WH, Bister K, Pawson A, Robins T, Mos-
covici C, Duesberg PH. Fujinami sarcoma 
virus: an avian RNA tumor virus with a unique 
transforming gene. Proc Natl Acad Sci USA. 
1980;77(4):2018–2022.
 48. Voisset E, Lopez S, Dubreuil P, De Sepulveda P. 
The tyrosine kinase FES is an essential effec-
tor of KITD816V proliferation signal. Blood. 
2007;110(7):2593–2599.
 49. Craig AW. FES/FER kinase signaling in hemato-
poietic cells and leukemias. Front Biosci (Land-
mark Ed). 2012;17:861–875.
 50. Bardelli A, et al. Mutational analysis of the 
tyrosine kinome in colorectal cancers. Science. 
2003;300(5621):949.
 51. Sangrar W, Zirgnibl RA, Gao Y, Muller WJ, 
Jia Z, Greer PA. An identity crisis for fps/fes: 
oncogene or tumor suppressor? Cancer Res. 
2005;65(9):3518–3522.
 52. Easty DJ, Herlyn M, Bennett DC. Abnormal pro-
tein tyrosine kinase gene expression during mel-
anoma progression and metastasis. Int J Cancer. 
1995;60(1):129–136.
 53. Fleuren ED, Zhang L, Wu J, Daly RJ. The 
kinome ‘at large’ in cancer. Nat Rev Cancer. 
2016;16(2):83–98.
 54. Davis MI, et al. Comprehensive analysis of 
kinase inhibitor selectivity. Nat Biotechnol. 
2011;29(11):1046–1051.
Downloaded from http://www.jci.org on May 5, 2017.   https://doi.org/10.1172/JCI91291
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 6 jci.org
 55. Hellwig S, et al. Small-molecule inhibitors of 
the c-Fes protein-tyrosine kinase. Chem Biol. 
2012;19(4):529–540.
 56. Anastassiadis T, Deacon SW, Devarajan K, 
Ma H, Peterson JR. Comprehensive assay of 
kinase catalytic activity reveals features of 
kinase inhibitor selectivity. Nat Biotechnol. 
2011;29(11):1039–1045.
 57. Rimm DL, Caca K, Hu G, Harrison FB, Fearon 
ER. Frequent nuclear/cytoplasmic localization of 
beta-catenin without exon 3 mutations in malig-
nant melanoma. Am J Pathol. 1999;154(2):325–329.
 58. Omholt K, Platz A, Ringborg U, Hansson J. Cyto-
plasmic and nuclear accumulation of beta-catenin 
is rarely caused by CTNNB1 exon 3 mutations 
in cutaneous malignant melanoma. Int J Cancer. 
2001;92(6):839–842.
 59. Forbes SA, et al. COSMIC (the Catalogue of Somat-
ic Mutations in Cancer): a resource to investigate 
acquired mutations in human cancer. Nucleic Acids 
Res. 2010;38(Database issue):D652–D657.
 60. Larue L, Delmas V. The WNT/Beta-catenin path-
way in melanoma. Front Biosci. 2006;11:733–742.
 61. Delmas V, et al. Beta-catenin induces immor-
talization of melanocytes by suppressing 
p16INK4a expression and cooperates with 
N-Ras in melanoma development. Genes Dev. 
2007;21(22):2923–2935.
 62. Pandolfi S, Montagnani V, Lapucci A, Stecca 
B. HEDGEHOG/GLI-E2F1 axis modulates 
iASPP expression and function and regulates 
melanoma cell growth. Cell Death Differ. 
2015;22(12):2006–2019.
 63. Jalili A, et al. NVP-LDE225, a potent and selec-
tive SMOOTHENED antagonist reduces mel-
anoma growth in vitro and in vivo. PLoS One. 
2013;8(7):e69064.
 64. Stecca B, et al. Melanomas require HEDGE-
HOG-GLI signaling regulated by interactions 
between GLI1 and the RAS-MEK/AKT pathways. 
Proc Natl Acad Sci U S A. 2007;104(14):5895–5900.
 65. Bosenberg M, et al. Characterization of melano-
cyte-specific inducible Cre recombinase trans-
genic mice. Genesis. 2006;44(5):262–267.
 66. Dankort D, Filenova E, Collado M, Serrano M, 
Jones K, McMahon M. A new mouse model to 
explore the initiation, progression, and therapy 
of BRAFV600E-induced lung tumors. Genes Dev. 
2007;21(4):379–384.
 67. Mercer K, et al. Expression of endogenous 
oncogenic V600EB-raf induces proliferation 
and developmental defects in mice and trans-
formation of primary fibroblasts. Cancer Res. 
2005;65(24):11493–11500.
 68. Lesche R, et al. Cre/loxP-mediated inactivation 
of the murine Pten tumor suppressor gene.  
Genesis. 2002;32(2):148–149.
 69. Jonkers J, Meuwissen R, van der Gulden H, 
Peterse H, van der Valk M, Berns A. Synergistic 
tumor suppressor activity of BRCA2 and p53 in a 
conditional mouse model for breast cancer. Nat 
Genet. 2001;29(4):418–425.
 70. Srinivas S, et al. Cre reporter strains produced by 
targeted insertion of EYFP and ECFP into the 
ROSA26 locus. BMC Dev Biol. 2001;1:4.
 71. Serrano M, Lee H, Chin L, Cordon-Cardo C, 
Beach D, DePinho RA. Role of the INK4a locus 
in tumor suppression and cell mortality. Cell. 
1996;85(1):27–37.
 72. Fenouille N, et al. The epithelial-mesenchymal 
transition (EMT) regulatory factor SLUG (SNAI2) 
is a downstream target of SPARC and AKT in 
promoting melanoma cell invasion. PLoS One. 
2012;7(7):e40378.
 73. Tichet M, et al. Tumour-derived SPARC drives 
vascular permeability and extravasation through 
endothelial VCAM1 signalling to promote metas-
tasis. Nat Commun. 2015;6:6993.
 74. Mascré G, et al. Distinct contribution of stem 
and progenitor cells to epidermal maintenance. 
Nature. 2012;489(7415):257–262.
 75. Li H, Durbin R. Fast and accurate short read 
alignment with Burrows-Wheeler transform.  
Bioinformatics. 2009;25(14):1754–1760.
 76. McKenna A, et al. The Genome Analysis Toolkit: 
a MapReduce framework for analyzing next- 
generation DNA sequencing data. Genome Res. 
2010;20(9):1297–1303.
 77. Albertson DG, Collins C, McCormick F, Gray JW. 
Chromosome aberrations in solid tumors.  
Nat Genet. 2003;34(4):369–376.
 78. Wang K, Li M, Hakonarson H. ANNOVAR: 
functional annotation of genetic variants from 
high-throughput sequencing data. Nucleic Acids 
Res. 2010;38(16):e164.
 79. Wang K, et al. PennCNV: an integrated hidden 
Markov model designed for high-resolution 
copy number variation detection in whole- 
genome SNP genotyping data. Genome Res. 
2007;17(11):1665–1674.
 80. Van Loo P, et al. Allele-specific copy number 
analysis of tumors. Proc Natl Acad Sci U S A. 
2010;107(39):16910–16915.
 81. Mermel CH, Schumacher SE, Hill B, Meyerson 
ML, Beroukhim R, Getz G. GISTIC2.0 facilitates 
sensitive and confident localization of the tar-
gets of focal somatic copy-number alteration in 
human cancers. Genome Biol. 2011;12(4):R41.
Downloaded from http://www.jci.org on May 5, 2017.   https://doi.org/10.1172/JCI91291
